Related Experiment Video
Updated: Sep 27, 2025
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for
Thapi D Rao1,2, Mengyao Xu3, Stephanie Eng1,4
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract:
Significant strides have been made in the development of precision therapeutics for cancer. Aberrantly expressed glycoproteins represent a potential avenue for therapeutic development. The MUC16/CA125 glycoprotein serves as a biomarker of disease and a driver of malignant transformation in epithelial ovarian cancer. Previously, we demonstrated a proof-of-principle approach to selectively targeting MUC16+ cells. In this report, we performed a synthetic lethal kinase screen using a human kinome RNAi library and identified key pathways preferentially targetable in MUC16+ cells using isogenic dual-fluorescence ovarian cancer cell lines. Using a separate approach, we performed high-content small-molecule screening of six different libraries of 356,982 compounds for MUC16/CA125-selective agents and identified lead candidates that showed preferential cytotoxicity in MUC16+ cells. Compounds with differential activity were selected and tested in various other ovarian cell lines or isogenic pairs to identify lead compounds for structure-activity relationship (SAR) selection. Lead siRNA and small-molecule inhibitor candidates preferentially inhibited invasion of MUC16+ cells in vitro and in vivo, and we show that this is due to decreased activation of MAPK, and non-receptor tyrosine kinases. Taken together, we present a comprehensive screening approach to the development of a novel class of MUC16-selective targeted therapeutics and identify candidates suitable for further clinical development.
Insights
Researchers identified new targeted therapies for ovarian cancer by screening for compounds that selectively kill MUC16-positive cancer cells. These novel therapeutics show promise for inhibiting cancer invasion and advancing precision medicine.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Aberrantly expressed glycoproteins like MUC16/CA125 are implicated in epithelial ovarian cancer progression.
- MUC16/CA125 is a validated biomarker and a driver of malignant transformation.
- Targeting MUC16-positive cells offers a promising strategy for precision cancer therapeutics.
Purpose of the Study:
- To identify novel therapeutic targets and agents selective for MUC16-expressing ovarian cancer cells.
- To investigate pathways preferentially targetable in MUC16-positive cells.
- To develop a new class of MUC16-selective targeted therapeutics.
Main Methods:
- Conducted a synthetic lethal kinase screen using a human kinome RNAi library.
- Performed high-content small-molecule screening of over 350,000 compounds.
- Utilized isogenic dual-fluorescence ovarian cancer cell lines for pathway identification.
- Validated lead candidates through in vitro and in vivo invasion assays.
Main Results:
- Identified key pathways (MAPK, non-receptor tyrosine kinases) preferentially targetable in MUC16+ cells.
- Discovered lead small-molecule and siRNA candidates with preferential cytotoxicity against MUC16+ cells.
- Demonstrated that lead candidates inhibit MUC16+ cell invasion by decreasing MAPK and tyrosine kinase activation.
- Confirmed preferential inhibition of invasion in vitro and in vivo.
Conclusions:
- Developed a comprehensive screening approach for MUC16-selective therapeutics.
- Identified novel lead candidates for targeted ovarian cancer therapy.
- These MUC16-selective agents show potential for clinical development in ovarian cancer treatment.
